An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice.
As Brucella infections occur mainly through mucosal surfaces, the development of mucosal administered vaccines could be radical for the control of brucellosis. In this work we evaluated the potential of Brucella abortus 19 kDa outer membrane protein (U-Omp19) as an edible subunit vaccine against brucellosis. We investigated the protective immune response elicited against oral B. abortus infection after vaccination of mice with leaves from transgenic plants expressing U-Omp19; or with plant-made or E. coli-made purified U-Omp19. All tested U-Omp19 formulations induced protection against Brucella when orally administered without the need of adjuvants. U-Omp19 also induced protection against a systemic challenge when parenterally administered. This built-in adjuvant ability of U-Omp19 was independent of TLR4 and could be explained at least in part by its capability to activate dendritic cells in vivo. While unadjuvanted U-Omp19 intraperitoneally administered induced a specific Th1 response, following U-Omp19 oral delivery a mixed specific Th1-Th17 response was induced. Depletion of CD4(+) T cells in mice orally vaccinated with U-Omp19 resulted in a loss of the elicited protection, indicating that this cell type mediates immune protection. The role of IL-17 against Brucella infection has never been explored. In this study, we determined that if IL-17A was neutralized in vivo during the challenge period, the mucosal U-Omp19 vaccine did not confer mucosal protection. On the contrary, IL-17A neutralization during the infection did not influence at all the subsistence and growth of this bacterium in PBS-immunized mice. All together, our results indicate that an oral unadjuvanted vaccine based on U-Omp19 induces protection against a mucosal challenge with Brucella abortus by inducing an adaptive IL-17 immune response. They also indicate different and important new aspects i) IL-17 does not contribute to reduce the bacterial burden in non vaccinated mice and ii) IL-17 plays a central role in vaccine mediated anti-Brucella mucosal immunity.
Laboratorio de Inmunogenética, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Karina A
KA
Pasquevich
Andrés E
AE
Ibañez
Lorena M
LM
Coria
Clara
C
García Samartino
Silvia M
SM
Estein
Astrid
A
Zwerdling
Paula
P
Barrionuevo
Fernanda S
FS
Oliveira
Christine
C
Seither
Heribert
H
Warzecha
Sergio C
SC
Oliveira
Guillermo H
GH
Giambartolomei
Juliana
J
Cassataro
D056704:Adaptive Immunity; D000818:Animals; D000942:Antigens, Bacterial / Q000627:therapeutic use*; D001425:Bacterial Outer Membrane Proteins / Q000627:therapeutic use*; D002004:Brucella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D002003:Brucella abortus / Q000276:immunology*; D002006:Brucellosis / Q000517:prevention & control; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology*; D008074:Lipoproteins / Q000627:therapeutic use*; D051379:Mice; D018417:Th1 Cells / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology
D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D002004:Brucella Vaccine; D020381:Interleukin-17; D008074:Lipoproteins; C097319:OMP19 protein, Brucella abortus
Am J Respir Cell Mol Biol. 2001 Sep;25(3):335-40
11588011
Cytokine. 2008 Feb;41(2):79-83
18218322
Vet Microbiol. 2008 Dec 10;132(3-4):302-11
18565697
Proc Natl Acad Sci U S A. 2004 May 4;101(18):6852-7
15103020
Infect Immun. 1990 Jul;58(7):2048-55
2114357
Annu Rev Immunol. 2009;27:485-517
19132915
J Biotechnol. 1999 Jul 30;73(1):1-33
10483112
J Immunol. 2008 Dec 1;181(11):7891-901
19017979
Vaccine. 2007 Aug 10;25(32):5958-67
17600596
Immunology. 2001 Aug;103(4):511-8
11529943
Nat Med. 2008 Apr;14(4):421-8
18376406
Vaccine. 2002 Jun 7;20(19-20):2431-8
12057597
Infect Immun. 2009 Nov;77(11):5181-9
19703982
Infect Immun. 2003 May;71(5):2326-30
12704101
Vaccine. 2003 Jan 30;21(7-8):803-8
12531364
Clin Vaccine Immunol. 2007 Jul;14(7):869-74
17428946
Trends Microbiol. 2003 May;11(5):215-9
12781524
J Immunol. 2004 Oct 1;173(7):4635-42
15383598
Microbes Infect. 2001 Jan;3(1):43-8
11226853
J Immunol. 2010 May 1;184(9):5200-12
20351187
Immunity. 2009 Nov 20;31(5):799-810
19853481
Nat Med. 2005 Apr;11(4 Suppl):S45-53
15812489
J Immunol. 2006 Dec 1;177(11):7980-9
17114471
J Exp Med. 2005 Sep 19;202(6):761-9
16157683
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):192-8
19046777
FEMS Microbiol Rev. 2010 May;34(3):379-94
20180858
Trends Mol Med. 2002 Jul;8(7):324-9
12114111
Nat Rev Immunol. 2006 Feb;6(2):148-58
16491139
Infect Immun. 1994 Feb;62(2):632-8
8300219
Methods. 2006 Feb;38(2):150-7
16431131
Curr Drug Deliv. 2005 Oct;2(4):383-93
16305441
Microbes Infect. 2008 Jul;10(9):1010-3
18664389
Microbes Infect. 2000 Apr;2(5):481-8
10865193
Trends Immunol. 2009 Jan;30(1):23-32
19059004
Vaccine. 2005 Mar 7;23(15):1804-13
15734046
Nat Med. 2005 Apr;11(4 Suppl):S63-8
15812492
Infect Immun. 2003 Oct;71(10):5750-5
14500496
Vaccine. 2007 May 30;25(22):4437-46
17442465
Bull World Health Organ. 2003;81(12):867-76
14997239
Infect Immun. 2007 Jan;75(1):299-305
17088355
Immunobiology. 2009;214(6):467-74
19150742
Adv Biotechnol Processes. 1990;13:147-68
2185782
Infect Immun. 1999 Sep;67(9):4960-2
10456959
PLoS Pathog. 2009 Dec;5(12):e1000703
20041174
Microbiol Immunol. 2007;51(12):1139-47
18094532
Infect Immun. 2002 Apr;70(4):1915-23
11895955
J Immunol. 2009 Dec 15;183(12):8026-34
19923464
Mucosal Immunol. 2009 Sep;2(5):403-11
19587639
J Immunol. 2008 Oct 1;181(7):4965-75
18802100
Infect Immun. 1995 Jan;63(1):264-70
7806364
Infect Immun. 2004 Jul;72(7):4031-9
15213148
J Drug Target. 2003;11(8-10):489-93
15203917
Immunology. 2009 Feb;126(2):177-85
19125888
Infect Immun. 2005 Dec;73(12):8079-88
16299302
Int Immunol. 2008 Sep;20(9):1129-38
18599501
J Infect Dis. 2004 Aug 1;190(3):624-31
15243941
Vet Microbiol. 2002 Dec 20;90(1-4):367-82
12414157
Vet Microbiol. 2002 Dec 20;90(1-4):479-96
12414166
Anim Health Res Rev. 2005 Dec;6(2):199-209
16583782
J Immunol. 2007 Mar 15;178(6):3786-96
17339477
Crit Rev Immunol. 2006;26(5):407-42
17341186
Infect Immun. 2005 Oct;73(10):6537-46
16177328
Nat Immunol. 2007 Apr;8(4):369-77
17351619
Infect Immun. 2009 Jan;77(1):436-45
18981242
Eur J Immunol. 2009 Feb;39(2):426-38
19180464
Vaccine. 2004 Sep 3;22(25-26):3435-9
15308369